Patient survey 2024
Earlier this year, we asked people affected by a liver condition across the UK to share their experiences of diagnosis, care and treatment. Thousands of responses provided us with invaluable insights into the patient journey, highlighting both positive experiences...
More evidence of the importance of opt-out hepatitis B and C testing
A new report launched today provides yet more evidence for The British Liver Trust’s call for routine, opt-out hepatitis B and hepatitis C testing. The report shares the latest findings from the Emergency department bloodborne virus opt-out testing programme. In total...
Can AI work out the best dose of immunosuppressants after a liver transplant?
Machine learning is a type of AI. It is a developing and exciting tool which can be useful for making predictions. But can it be used to help guide the correct dose of medicines? For example, the immunosuppressant tacrolimus, which is used after liver transplants. A...
Elafibranor approved by NICE for primary biliary cholangitis
The National Institute for Health and Clinical Excellence (NICE) has today recommended elafibranor as a second-line treatment for primary biliary cholangitis (PBC). The British Liver Trust collated insight from patients and submitted evidence to NICE as part of the...